Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Saegis Pharmaceuticals Names Robert Gerlai Vice President of Research
Ist Teil von
Business Wire, 2002, p.1
Ort / Verlag
New York: Business Wire
Erscheinungsjahr
2002
Link zum Volltext
Beschreibungen/Notizen
In both academic and industry settings, Dr. [Gerlai]'s research has focused on the genetic and biological mechanisms of behavioral and neural plasticity, including memory and learning. Prior to joining Saegis Pharmaceuticals, he established a cognitive behavioral group at Eli Lilly and Co. and made numerous discoveries leading to clinical trials or patent applications. Gerlai joined Lilly from Genentech, where he was responsible for directing a preclinical animal behavior testing core and was group leader on the functional analysis of EphA receptor tyrosine kinases. "In addition to its promising Phase II clinical trials, Saegis Pharmaceuticals is developing a discovery platform that will allow the company to identify novel molecular targets for drug development in the area of age dependent memory dysfunction and mild cognitive impairment," said Dr. Gerlai. "These are particularly promising times for the company and I'm very excited to lead the research effort to discover new therapies that improve learning and memory."